AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2

Blood

Volumn 116, Issue 2, 2010, Pages 254-266

  Wang, Wei ^a,b   Schwemmers, Sven ^a,b   Hexner, Elizabeth O ^c   Pahl, Heike L ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; JANUS KINASE 2; MESSENGER RNA; TRANSCRIPTION FACTOR MAFK; TRANSCRIPTION FACTOR RUNX1; JAK2 PROTEIN, HUMAN; NFE2 PROTEIN, HUMAN; RUNX1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NF E2 P45 SUBUNIT;

ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; GRANULOCYTE; HUMAN; HUMAN CELL; MYELOID METAPLASIA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; RNA INTERFERENCE; THROMBOCYTHEMIA; BIOSYNTHESIS; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MYELOPROLIFERATIVE DISORDER; NORTHERN BLOTTING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLOTTING, NORTHERN; BLOTTING, WESTERN; CHROMATIN IMMUNOPRECIPITATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; NF-E2 TRANSCRIPTION FACTOR, P45 SUBUNIT; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSFECTION;

EID: 77955507360     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-254664     Document Type: Article

References (50)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. (Pubitemid 40663494)
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061. (Pubitemid 40386783)
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. (Pubitemid 40570926)
4. Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108(4):1377-1380.
5. Cario H, Goerttler PS, Steimle C, Levine RL, Pahl HL. The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol. 2005;130(5):800-801.
6. Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446-449.
7. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
8. Goerttler PS, Kreutz C, Donauer J, et al. Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2. Br J Haematol. 2005;129(1):138-150.
9. Shivdasani RA, Rosenblatt MF, Zucker-Franklin D, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell. 1995;81(5):695-704.
10. Mutschler M, Magin AS, Buerge M, et al. NF-E2 overexpression delays erythroid maturation and increases erythrocyte production. Br J Haematol. 2009;164(2):203-217.
11. Kralovics R, Teo SS, Buser AS, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005;106(10):3374-3376.
12. Vannucchi AM, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia. 2006;20(6):1055-1060. (Pubitemid 43797297)
13. Pischedda C, Cocco S, Melis A, et al. Isolation of a differentially regulated splicing isoform of human NF-E2. Proc Natl Acad Sci U S A. 1995;92(8):3511-3515.
14. Moroni E, Mastrangelo T, Razzini R, et al. Regulation of mouse p45 NF-E2 transcription by an erythroid-specific GATA-dependent intronic alternative promoter. J Biol Chem. 2000;275(14):10567-10576.
15. Toki T, Itoh J, Arai K, et al. Abundant expression of erythroid transcription factor P45 NF-E2 mRNA in human peripheral granurocytes. Biochem Biophys Res Commun. 1996;219(3):760-765.
16. McCormack MP, Hall MA, Schoenwaelder SM, et al. A critical role for the transcription factor Scl in platelet production during stress thrombopoiesis. Blood. 2006;108(7):2248-2256.
17. Couronne O, Poliakov A, Bray N, et al. Strategies and tools for whole-genome alignments. Genome Res. 2003;13(1):7-11.
18. Marinescu V, Kohane I, Riva A. MAPPER: a search engine for the computational identification of putative transcription factor binding sites in multiple genomes. BMC Bioinformatics. 2005;6:79-85.
19. Swerdlow S, Campo E, Harris N. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IRAC Press; 2009
20. Steimle C, Lehmann U, Temerinac S, et al. Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F. Ann Hematol. 2007;86(4):239-244. (Pubitemid 46351398)
21. Temerinac S, Klippel S, Strunck E, et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in Polycythemia rubra vera. Blood. 2000;95(8):2569-2576.
22. Toki T, Arai K, Terui K, et al. Functional characterization of the two alternative promoters of human p45 NF-E2. Exp Hematol. 2000;28(10):1113-1119.
23. Kohlhuber F, Rogers NC, Watling D, et al. A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. Mol Cell Biol. 1997;17(2):695-706.
24. Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood. 2008;111(12):5663-5671.
25. Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell. 2002;9(3):601-610. (Pubitemid 34273790)
26. Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119(7):941-953.
27. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 1989;17(15):6419.
28. Libermann TA, Pan Z, Akbarali Y, et al. AML1 (CBFalpha2) cooperates with B-cell-specific activating protein (BSAP/PAX5) in activation of the B-cell-specific BLK gene promoter. J Biol Chem. 1999;274(35):24671-24676. (Pubitemid 29404666)
29. Quentmeier H, MacLeod RA, Zaborski M, Drexler HG. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia. 2006;20(3):471-476.
30. Huang G, Zhang P, Hirai H, et al. PU. 1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet. 2008;40(1):51-60.
31. Frank R, Zhang J, Uchida H, Meyers S, Hiebert SW, Nimer SD. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene. 1995;11(12):2667-2674. (Pubitemid 26023835)
32. Linggi B, Muller-Tidow C, van de Locht L, et al. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med. 2002;8(7):743-750.
33. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84(2):321-330. (Pubitemid 26042836)
34. Redondo JM, Pfohl JL, Hernandez-Munain C, Wang S, Speck NA, Krangel MS. Indistinguishable nuclear factor binding to functional core sites of the T-cell receptor delta and murine leukemia virus enhancers. Mol Cell Biol. 1992;12(11):4817-4823.
35. Zhang DE, Fujioka K, Hetherington CJ, et al. Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol Cell Biol. 1994;14(12):8085-8095.
36. Song WJ, Sullivan MG, Legare RD, et al. Haplo-insufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23(2):166-175.
37. Ho CY, Otterud B, Legare RD, et al. Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2. Blood. 1996;87(12):5218-5224.
38. Yanagida M, Osato M, Yamashita N, et al. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice. Oncogene. 2005;24(28):4477-4485.
39. Ichikawa M, Asai T, Saito T, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med. 2004;10(3):299-304.
40. Kuo YH, Landrette SF, Heilman SA, et al. Cbf beta-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia. Cancer Cell. 2006;9(1):57-68.
41. Okada H, Watanabe T, Niki M, et al. AML1(-/-) embryos do not express certain hematopoiesis-related gene transcripts including those of the PU.1 gene. Oncogene. 1998;17(18):2287-2293.
42. Lübbert M, Muller-Tidow C, Hofmann WK, Koeffler HP. Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapy. J Cell Biochem. 2008;104(6):2059-2070.
43. Alcalay M, Meani N, Gelmetti V, et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest. 2003;112(11):1751-1761.
44. Dunne J, Cullmann C, Ritter M, et al. siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts. Oncogene. 2006;25(45):6067-6078.
45. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16):1617-1628. (Pubitemid 38528701)
46. Elagib KE, Goldfarb AN. Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation. Cancer Lett. 2007;251(2):179-186.
47. Vangala RK, Heiss-Neumann MS, Rangatia JS, et al. The myeloid master regulator transcription factor PU. 1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood. 2003;101(1):270-277.
48. Westendorf JJ, Yamamoto CM, Lenny N, Downing JR, Selsted ME, Hiebert SW. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol. 1998;18(1):322-333.
49. Rosenbauer F, Tenen DG. Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol. 2007;7(2):105-117. (Pubitemid 46174858)
50. Ding Y, Harada Y, Imagawa J, Kimura A, Harada H. AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood. 2009;114(25):5201-5205.